Oncology

Your Article Summary

See Latest Articles

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Annals of Oncology, 06/02/09

Terpos E et al. - In a review of the current evidence for use of bisphosphonates (BPs) in multiple myeloma (MM) and provide European Union-specific recommendations to support the clinical practice of treating myeloma bone disease, it appears that BPs are an essential component of MM therapy for minimizing skeletal morbidity. Recent retrospective data indicate that a modified dosing regimen and preventive measures can greatly reduce the incidence of osteonecrosis of the jaw (ONJ).

• An interdisciplinary, expert panel of specialists on MM and myeloma-related bone disease convened for a face-to-face meeting to review and assess evidence and develop recommendations.
• The panel reviewed and graded evidence available from randomized clinical trials, clinical practice guidelines, and the body of published literature.
• Where published data were weak or unavailable, the panel used their own clinical experience to put forward recommendations based solely on their expert opinions.

• The panel recommends the use of BPs in MM pts suffering from lytic bone disease or severe osteoporosis.
• Intravenous administration may be preferable; however, oral administration can be considered for pts unable to make hospital visits.
• Dosing should follow approved indications with adjustments if necessary.
• BPs are well tolerated, but preventive steps should be taken to avoid renal impairment and ONJ.
• The panel agrees that BPs should be given for 2 yrs, but this may be extended if there is evidence of active myeloma bone disease.
• Initial therapy of ONJ should include discontinuation of BPs until healing occurs; BPs should be restarted if there is disease progression.

Today in Myeloproliferative Dz...keeping you current

Receive free subspecialty "5-minute updates" via email

Bortezomib: a new therapeutic option for POEMS syndrome
European Journal of Haematology, 10/13/09

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial : The Lancet Oncology
The Lancet Oncology - Online First, 10/23/09

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Journal of Clinical Oncology, 10/16/09

See All of Myeloproliferative Dz